Study guide
7.5 Immune Reconstitution & the Inactivated Re-Vaccination Schedule
Transplantation and Cellular Therapy Certified Nurse TCTCN
Track your progress as you read
Finished sections get a check mark.
1 Introduction & Exam Overview
1.1 The TCTCN Credential: Rename, Scope & Official Test Blueprint 1.2 TCTCN Eligibility, Test-Day Logistics, Scoring & Renewal 1.3 Building the Study Plan & Clinical Prioritization Framework 1.4 Clinical Triage Rehearsal & Exam-Day Question Strategy
2 Chapter 2: Foundations of Transplantation & Cellular Biology
2.1 Hematopoietic Lineage, the MHC & HLA Class I vs Class II Biology 2.2 HLA Typing Resolution, Donor Matching, DSA & ABO Compatibility 2.3 Disease Indications & the Cellular Therapy Modality Map 2.4 Pre-Transplant Risk Stratification & Organ Suitability Assessment 2.5 Stem Cell & Cellular Product Sources: Donor Selection Hierarchy 2.6 Conditioning Regimens & Lymphodepletion Principles 2.7 Recipient and Caregiver Education Across the Continuum
3 Chapter 3: Product Collection, Processing & Infusion Procedures
3.1 Stem Cell Mobilization: Niche Biology, Agents & CD34+ Collection Targets 3.2 Apheresis Nursing Care: Vascular Access, Citrate Toxicity & Donor Safety 3.3 Graft Engineering, ABO-Directed Processing & Cryopreservation Science 3.4 DMSO Toxicity, Premedication & Time-Critical Thawed Product Administration 3.5 Pre-Administration Verification, Equipment & CAR T Infusion Readiness 3.6 Infusion Monitoring & Acute Reaction Differential Management 3.7 Engraftment Definitions, Kinetics & Factors Impairing Recovery 3.8 Graft Failure Classification & Donor Chimerism Tracking
4 Chapter 4: Acute Post-HSCT Complications & Graft-versus-Host Disease
4.1 Acute GVHD: Billingham's Postulates, Classification & the Ferrara 3-Phase Model 4.2 Acute GVHD Organ Manifestations, Histopathology & MAGIC Staging 4.3 MAGIC Overall Grading & Acute GVHD Plasma Biomarkers 4.4 Acute GVHD Prophylaxis, First-Line Steroids & Steroid-Refractory Therapy 4.5 SOS/VOD: Microvascular Pathophysiology & Risk Stratification 4.6 SOS/VOD Diagnostic Criteria, Surveillance & Defibrotide Therapy 4.7 TA-TMA: Complement Pathophysiology, Harmonized Criteria & Differential 4.8 TA-TMA Management, Complement-Directed Therapy & Other Endothelial Syndromes
5 Chapter 5: Post-Transplant Infections & Supportive Care
5.1 Neutropenic Fever, Pre-Engraftment Phase & Empiric Antimicrobial Therapy 5.2 CMV: Risk Stratification, Letermovir Prophylaxis & DNAemia Treatment 5.3 EBV/PTLD, HHV-6 Encephalitis, BK Cystitis, Adenovirus, HSV & VZV 5.4 Invasive Fungal Infections (Aspergillus, Candida, Mucor) & PJP Prophylaxis 5.5 Supportive Care in Aplasia: Transfusion Guidelines, Oral Mucositis & Nutrition
6 Chapter 6: Post-Cellular Therapy Management, CRS & ICANS
6.1 CAR Structural Architecture, Generations & Costimulatory Domain Biology 6.2 The Vein-to-Vein Lifecycle, In Vivo Kinetics & On-Target B-Cell Aplasia 6.3 CRS Pathophysiology, Clinical Kinetics & Inflammatory Biomarkers 6.4 ASTCT CRS Grading, Tocilizumab & Escalation Management 6.5 ICANS: Assessment, ICE Scoring & Clinical Management 6.6 Delayed Cellular Toxicities: Prolonged Cytopenias, B-Cell Aplasia & IEC-HS 6.7 Symptom Management and Functional Recovery After Cellular Therapy
7 Chapter 7: Chronic GVHD & Long-Term Survivorship
7.1 Chronic GVHD: Three-Phase Immunobiology & NIH Classification 7.2 Chronic GVHD Diagnostic Manifestations, BOS & NIH Global Severity Scoring 7.3 Chronic GVHD: Systemic, Steroid-Sparing & Multidisciplinary Therapy 7.4 Late Effects: Endocrine, Cardiovascular, Bone Health & Secondary Malignancies 7.5 Immune Reconstitution & the Inactivated Re-Vaccination Schedule 7.6 Live Vaccines, Household Contact Precautions & Survivorship Care Plans 7.7 Post-HSCT Relapse: Surveillance, Immunologic Manipulation & Treatment
8 Chapter 8: Quality of Life, Ethics & Professional Practice Standards
8.1 Psychosocial Trajectories, Distress Screening & Delirium Assessment 8.2 Caregiver Planning, Financial & Cultural Navigation, and Sexual Health 8.3 Palliative Care Integration, Advance Directives & Ethical Considerations 8.4 FACT-JACIE Quality Standards, CIBMTR / NMDP Reporting & Compliance 8.5 Evidence-Based Practice, Discharge Education & Quality Improvement
7.5 Immune Reconstitution & the Inactivated Re-Vaccination Schedule
Key Takeaways Explain This Topic AI
HCT can substantially reduce prior vaccine protection, so recipients are generally revaccinated as a primary series; timing depends on vaccine, transplant, GVHD, immunosuppression, season/outbreak and expected response.
Current CDC HCT pneumococcal guidance uses three PCV20 doses at least four weeks apart starting 3-6 months after HCT plus a fourth at least six months later or at least 12 months after HCT, whichever is later; alternative products have different schedules.
Revaccination is a primary series rather than a booster because transplant does not preserve pre-transplant immunologic memory, so prior childhood or adult vaccination history does not shorten the schedule.
Inactivated vaccines can generally be started while a patient remains on immunosuppression for mild chronic GVHD, though the expected antibody response may be reduced and timing follows the program's plan.
Last updated: September 2026
Post-Transplant Re-Vaccination, Infection Prevention & Survivorship Care Plans
Quick Clinical Summary: HCT can erase or weaken prior vaccine protection, so recipients are generally revaccinated with a primary-series approach. Timing is vaccine- and patient-specific: pneumococcal vaccination commonly begins 3–6 months after HCT, other inactivated vaccines follow the current transplant schedule, and live vaccines are considered no earlier than 24 months only when the patient is immunocompetent, has no active GVHD, and is off immunosuppression. A survivorship plan records doses, deferrals, immune therapy/IVIG context, responsibilities, and follow-up.
1. Post-Transplant Immune Reconstitution & Rationale for Re-Vaccination
Following conditioning and stem cell infusion, the recipient's immune system undergoes a protracted, recapitulated ontogeny: IMMUNE RECOVERY AFTER HCT
- Early: innate-cell recovery and profound infection risk
- > Next: variable NK/T-cell recovery, still influenced by conditioning, GVHD and therapy
- > Later: B-cell, antibody and naive-T-cell recovery may remain incomplete for months to years
- > Vaccination decisions use vaccine-specific timing plus the patient's current immune state
- Why Pre-Transplant Immunity Is Lost
Humoral Ablation: Conditioning chemotherapy and irradiation destroy host plasma cell niches in bone marrow and spleen.
Donor Titer Decay: While donor memory B cells are transferred in allogeneic grafts, they fail to maintain protective antibody titers beyond 6 to 12 months without scheduled antigen re-exposure.
Thymic Delay: Regeneration of naive CD4+ helper T cells (CD4+CD45RA+) via the thymus is exceedingly slow, especially in adults or patients who suffered GVHD-mediated thymic epithelial damage. Without CD4+ help, B cells cannot undergo effective class-switching or long-lived memory generation without booster vaccinations.
2. Inactivated Re-Vaccination Schedule
Inactivated, recombinant, toxoid, and subunit vaccines cannot replicate. Start dates vary by vaccine, transplant type, outbreak/season, GVHD and immunosuppression, and expected response. The example below highlights the current CDC pneumococcal sequence; the transplant team should issue a patient-specific schedule rather than treating every row as one universal month:
Current pneumococcal sequence example
Begin PCV20 about 3–6 months after HCT when clinically appropriate.
Give three PCV20 doses at least 4 weeks apart.
Give a fourth PCV20 dose at least 6 months after dose 3 or at least 12 months after HCT, whichever is later.
If another pneumococcal product is used, follow the current CDC alternative schedule.
Vaccine Type Target Organisms Recommended Post-HCT Regimen & Timing Clinical Notes & ASTCT Guidance
Pneumococcal conjugate (PCV20) Streptococcus pneumoniae Four-dose HCT sequence: 3 doses at least 4 weeks apart starting about 3–6 months, then dose 4 at least 6 months after dose 3 or at least 12 months post-HCT, whichever is later. If using another pneumococcal product, follow the current CDC alternative schedule.
Diphtheria, tetanus, pertussis C. diphtheriae , C. tetani , B. pertussis Repeat a 3-dose primary series beginning on the current HCT schedule. Product selection and intervals depend on age and program guidance; do not assume one DTaP/Tdap substitution rule.
Inactivated polio (IPV) Poliovirus Repeat a 3-dose IPV series beginning on the current HCT schedule. Do not give OPV to the recipient; household-contact precautions depend on the actual product and current guidance.
Haemophilus influenzae type b (Hib) H. influenzae type b Repeat a 3-dose Hib series, commonly beginning 6–12 months after successful HCT. Follow the age- and program-specific interval; HCT recipients are vulnerable to encapsulated bacteria.
Hepatitis B (HepB) Hepatitis B virus Repeat the age-appropriate HepB primary series on the current HCT schedule. Product, interval and post-series serology/revaccination follow current national and transplant-program guidance; do not assume every product uses the same dose count.
Recombinant zoster (RZV / Shingrix) Varicella-zoster virus 2-dose series ; CDC recommends about 6–12 months after allogeneic HCT and 3–12 months after autologous HCT, preferably before stopping antiviral prophylaxis. Non-live; choose timing with the transplant team to optimize response.
Inactivated/recombinant influenza Seasonal influenza A and B Vaccinate annually; early post-HCT timing is season- and program-specific. Use a non-live product while immunocompromised and check the current age/product guidance.
Meningococcal (MenACWY and MenB) Neisseria meningitidis Use the current risk-based schedule and boosters. Indicated for defined risks such as anatomic/functional asplenia or complement-inhibitor therapy; GVHD alone is not a universal mandate.
COVID-19 SARS-CoV-2 Follow the current age- and immune-status-specific product schedule; HCT/CAR-T recipients may need revaccination beginning at least 3 months after therapy. Product/formula and additional doses change over time, so verify current CDC guidance.
Loading diagram... Post-HCT Re-Vaccination Protocol & Survivorship Care Pathway
3. Executing the Schedule at the Bedside
A vaccine schedule fails in practice for administrative reasons far more often than clinical ones, and most of those failures are preventable at the point of administration.
Verify eligibility at each dose, not once at the start. Immunosuppression, GVHD activity, recent antibody products, and B-cell-depleting therapy all change between visits. A patient cleared for a series in month six may be back on systemic therapy by month nine, so confirm current status against the plan before each administration rather than assuming the series carries forward.
Manage the injection in a thrombocytopenic patient. Intramuscular administration is generally acceptable at platelet counts the program considers safe, using the smallest appropriate needle gauge, avoiding aspiration, and applying firm pressure without rubbing for at least two minutes afterward. When counts are very low, coordinate the timing with the count trend or with a planned transfusion rather than deferring the vaccine indefinitely, and document the site so a subsequent hematoma can be attributed.
Document what a future clinician will need. Record product, manufacturer, lot number, expiration, dose, route, site, and date, plus the immunosuppression status at administration. A dose given during active immunosuppression may need to be repeated, and that judgment is impossible without the context.
Close the loop on serology where it is indicated. Some vaccines, notably hepatitis B, may be followed by post-series serologic testing with revaccination when the response is inadequate. Order sets do not always include it, and the result frequently arrives after the patient has transitioned to community care, so name the responsible clinician in the survivorship plan.
Reconcile against the immunization registry. Doses given at pharmacies, in the community, or during travel do not automatically appear in the transplant record. Check the registry at milestone visits and reconcile discrepancies rather than assuming the chart is complete.